相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis
Chonghui Hu et al.
MOLECULAR CANCER (2022)
Curcumin induces autophagic cell death in human thyroid cancer cells
Li Zhang et al.
TOXICOLOGY IN VITRO (2022)
A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro
Chitra Subramanian et al.
SURGERY (2021)
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
Viktoria F. Koehler et al.
THYROID (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer
Ying Wang et al.
INVESTIGATIONAL NEW DRUGS (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer
Hee Kyung Kim et al.
ONCOLOGY REPORTS (2021)
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
Katerina Jaklova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang et al.
CANCER CELL (2021)
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Janice Kim et al.
CLINICAL CANCER RESEARCH (2021)
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
Elisa Bonaldi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights
Asumi Iesato et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2021)
The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer
Zhongqin Gong et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer
Jianing Tang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy
Lin Run et al.
ENDOCRINE (2021)
CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation
Tin-Lok Wong et al.
HEPATOLOGY (2020)
STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells
Jiao Wu et al.
CANCER BIOMARKERS (2020)
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa et al.
CANCER CELL (2020)
Acetylcholine promotes the self-renewal and immune escape of CD133+thyroid cancer cells through activation of CD133-Akt pathway
Zhenglin Wang et al.
CANCER LETTERS (2020)
miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway
Zhenhua Hu et al.
CELL CYCLE (2020)
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
Husain Yar Khan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Haiyang Zhang et al.
MOLECULAR CANCER (2020)
Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer
Xinyi Wang et al.
MOLECULAR ONCOLOGY (2020)
VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid cancer
Shitu Chen et al.
TRANSLATIONAL ONCOLOGY (2020)
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
Emanuela Minna et al.
CANCERS (2020)
YAP confers resistance to vandetanib in medullary thyroid cancer
Huan Wang et al.
BIOCHEMISTRY AND CELL BIOLOGY (2020)
Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect
Luyuan Ma et al.
CANCER SCIENCE (2020)
KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma
Zheng Wang et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2020)
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
Maria E. Cabanillas et al.
THYROID (2020)
Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
Xiangrui Meng et al.
FRONTIERS IN ONCOLOGY (2020)
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel
Jie Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Keith C. Bible et al.
THYROID (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma
Zhongqiang Zhang et al.
CELL DEATH & DISEASE (2020)
CD63+Cancer-Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR-22
Yuan Gao et al.
ADVANCED SCIENCE (2020)
Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment
Zhenyu Xie et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Mijin Kim et al.
ENDOCRINOLOGY AND METABOLISM (2020)
Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
Xiangping Song et al.
THERANOSTICS (2020)
LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway
Wenyu Sun et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2020)
FAM129A regulates autophagy in thyroid carcinomas in an oncogene-dependent manner
Bruno Heidi Nozima et al.
ENDOCRINE-RELATED CANCER (2019)
MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells
Xiaoping Zhang et al.
ONCOGENE (2019)
Exosomes increased angiogenesis in papillary thyroid cancer microenvironment
Feng Wu et al.
ENDOCRINE-RELATED CANCER (2019)
JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells
Ken Shiraiwa et al.
THYROID (2019)
Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma
Ju Hye Jeong et al.
THYROID (2019)
Everolimus in Anaplastic Thyroid Cancer: A Case Series
Ethan J. Harris et al.
FRONTIERS IN ONCOLOGY (2019)
Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
Ryan Robb et al.
CLINICAL CANCER RESEARCH (2019)
KRAS G12V Mutation in Acquired resistance to Combined BRAF and MEK Inhibition in Papilary Thyroid Cancer
Dwight H. Owen et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer
In-Hye Ham et al.
MOLECULAR CANCER (2019)
Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness
Julia Ramirez-Moya et al.
ONCOGENE (2019)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
Chandan Kanta Das et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer
Jing Zhai et al.
CANCER LETTERS (2019)
Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis
Yao Yao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer
Seong-Keun Yoo et al.
NATURE COMMUNICATIONS (2019)
Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression
Laura Fozzatti et al.
SCIENTIFIC REPORTS (2019)
Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
Tomoko Ozeki et al.
SCIENTIFIC REPORTS (2019)
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
Josip Ljubas et al.
CANCERS (2019)
Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer
Cedric O. Renaud et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells
Fiorenza Giani et al.
BIOINFORMATICS (2019)
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
Teresa Di Desidero et al.
FRONTIERS IN ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
Young Shin Song et al.
CLINICAL CANCER RESEARCH (2019)
Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
Viswanath Gunda et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis
Brittelle E. Kessler et al.
ONCOGENE (2019)
Targeting mitochondria with Au- Ag@ Polydopamine nanoparticles for papillary thyroid cancer therapy
Wenjing Wang et al.
BIOMATERIALS SCIENCE (2019)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway
Wei Gao et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Drug resistance profiles of mutations in the RET kinase domain
Xuan Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells
Tiziana Notarangelo et al.
CANCER LETTERS (2018)
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna et al.
CLINICAL CANCER RESEARCH (2018)
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer
Shu-Fu Lin et al.
ENDOCRINE-RELATED CANCER (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
Shuai Lu et al.
CELL DEATH & DISEASE (2018)
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Takashi Nakaoku et al.
NATURE COMMUNICATIONS (2018)
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma
Zorica Milosevic et al.
CELLULAR ONCOLOGY (2018)
INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression
Hongyu Guan et al.
CELL AND BIOSCIENCE (2018)
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
Thomas C. Beadnell et al.
ONCOGENESIS (2018)
Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells
Yong Sang Lee et al.
NEOPLASIA (2018)
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway
Fukun Chen et al.
CANCER BIOLOGY & THERAPY (2018)
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
Jeffrey A. Knauf et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer
Haoran Feng et al.
CELL DEATH & DISEASE (2018)
Pericytes Elicit Resistance to Vemur1afenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF beta 1 Axis
Alessandro Prete et al.
CLINICAL CANCER RESEARCH (2018)
Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Weibin Wang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Alain Ravaud et al.
EUROPEAN JOURNAL OF CANCER (2017)
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of papillary thyroid carcinoma with a solid component
Ryuji Ohashi et al.
HUMAN PATHOLOGY (2017)
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Hyeyeun Lim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Guan-Nan Zhang et al.
PHARMACOLOGICAL RESEARCH (2017)
Role of Kruppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer
Su In Lee et al.
THYROID (2017)
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
Wei-Jun Wei et al.
THERANOSTICS (2017)
Synergistic Activity of N-hydroxy-7(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
Ki Cheong Park et al.
NEOPLASIA (2017)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis
Viswanath Gunda et al.
CANCER LETTERS (2017)
Cyp24a1 Attenuation Limits Progression of BrafV600E-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720
Minjing Zou et al.
CANCER RESEARCH (2017)
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer
Athanasios Bikas et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Correlative Analyses of RET and RAS Mutations in a Phase 3 Trial of Cabozantinib in Patients With Progressive, Metastatic Medullary Thyroid Cancer
Steven I. Sherman et al.
CANCER (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Biologic and Clinical Perspectives on Thyroid Cancer
James A. Fagin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
Brian P. Danysh et al.
ONCOTARGET (2016)
Amino acids and autophagy: their crosstalk, interplay and interlock
Chien-An A. Hu et al.
AMINO ACIDS (2015)
Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer
Ali Salajegheh et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
Douglas W. Ball et al.
ONCOLOGY REPORTS (2015)
The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
Valentina Tesori et al.
SCIENTIFIC REPORTS (2015)
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
Vincenzo Marotta et al.
ENDOCRINE (2015)
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1
Yi-Jun Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin
Y. Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
E. E. W. Cohen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Cancer stem-like cells and thyroid cancer
Zhenying Guo et al.
ENDOCRINE-RELATED CANCER (2014)
Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
Ramona Dadu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome
Ji Yun Yun et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)
E. Mato et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
V. Gunda et al.
CELL DEATH & DISEASE (2014)
Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells
Ling Lan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
SNAIL Induces Epithelial-to-Mesenchymal Transition and Cancer Stem Cell-Like Properties in Aldehyde Dehydroghenase-Negative Thyroid Cancer Cells
Kazuaki Yasui et al.
THYROID (2013)
Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
Kevin B. Kim et al.
THYROID (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Christine M. Chan et al.
CLINICAL CANCER RESEARCH (2012)
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
Katherine Thornton et al.
CLINICAL CANCER RESEARCH (2012)
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2
Shavali Shaik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Vlad C. Sandulache et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Sunitinib Exerts Only Limited Effects on the Proliferation and Differentiation of Anaplastic Thyroid Cancer Cells
Maria D'Agostino et al.
THYROID (2012)
MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets
Deepak Abraham et al.
CLINICAL CANCER RESEARCH (2011)
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells
Luigi Fiume et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models
Jae-Ho Cheong et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors
Luigi Fiume et al.
PHARMACOLOGICAL RESEARCH (2011)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
The Association of AMPK with ULK1 Regulates Autophagy
Jong Woo Lee et al.
PLOS ONE (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
分享论文
